DELAFIELD, Wis. (Stockpickr) -- Professional traders running mutual funds and hedge funds don't just look at a stock's price moves; they also track big changes in volume activity. Often when above-average volume moves into an equity, it precedes a large spike in volatility.
Major moves in volume can signal unusual activity, such as insider buying or selling -- or buying or selling by "superinvestors."
Unusual volume can also be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst. These types of traders like to get in well before a large spike, so it's always a smart move to monitor unusual volume. That said, remember to combine trend and price action with unusual volume. Put them all together to help you decipher the next big trend for any stock.
With that in mind, let's take a look at several stocks rising on unusual volume today.
Mako Surgical
Mako Surgical (MAKO) is a medical device company that markets its advanced robotic arm solution, joint specific applications for the knee and hip, and orthopedic implants for orthopedic procedures. This stock closed up 12.9% to $14.04 in Wednesday's trading session.
Top 5 Growth Stocks To Own For 2015: SunTrust Banks Inc.(STI)
SunTrust Banks, Inc. operates as the holding company for SunTrust Bank, which provides various financial services in the United States. The company?s Retail Banking segment offers consumer deposits, home equity lines, consumer lines, indirect auto, student lending, bank card, and other consumer loan and fee-based products. Its Diversified Commercial Banking segment provides commercial lending, financial risk management, capital raising, commercial card, and other treasury and payment solutions; insurance premium financing; and equipment and lease financing. The company?s Commercial Real Estate segment offers construction, mini-perm, and permanent real estate financing; capital raising services; financial risk management; treasury and payment solutions; and investment advisory and management services, as well as tailored financing and equity investment solutions. Its Corporate and Investment Banking segment provides investment banking products and services, such as strate gic advice, capital raising, and financial risk management; and traditional lending, leasing, treasury management, and institutional investment management services. The company?s Mortgage segment offers residential mortgage products. Its Wealth and Investment Management segment provides brokerage, professional investment management, and trust services; family office solutions; administration and custody services; administrative and investment solutions; escrow; and investment advisory services. The company also offers mortgage banking, credit-related insurance, asset management, securities brokerage, and capital market services. SunTrust Banks, Inc. serves individuals and families; businesses; institutions; and governmental agencies through its network of traditional and in-store branches, automated teller machines, Internet, and telephone. As of December 31, 2011, the company operated 1,659 full-service banking offices. The company was founded in 1891 and is headquartered in Atlanta, Georgia.
Advisors' Opinion:- [By Amanda Alix]
Now, smaller cousin SunTrust Banks Inc. (NYSE: STI ) inked a $320 million deal with government regulators concerning its own missteps in administering HAMP, a case in which the bank was charged with some of the same behavior as B of A ��such as lying to customers about the status of their applications, unopened piles of which were stacked so high in a storage room as to crack the floor joists beneath them.�
Top Rising Stocks To Watch Right Now: Acceleron Pharma Inc (XLRN)
Acceleron Pharma Inc., incorporated on June 13, 2003, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. The Company�� research focuses on the biology of the Transforming Growth Factor-Beta (TGF-b) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body. By coupling its discovery and development expertise, including its knowledge of the TGF-b superfamily, with its internal protein engineering and manufacturing capabilities, it has built a productive research and development platform that has generated clinical and preclinical protein therapeutic candidates with mechanisms of action.
The Company focuses on discovering and developing protein therapeutics that target a group of approximately 30 secreted proteins, or ligands, that are collectively referred to as the TGF-b superfamily. These ligands bind to subsets of 12 different receptors on the surface of cells, triggering intra-cellular changes in gene expression that guide cell growth and differentiation. The TGF-b superfamily ligands and their receptors represent an under-explored and diverse set of drug targets with the potential to yield therapeutics that modulate the growth and repair of diseased cells and tissues.
The Company has three internally discovered protein therapeutic candidates that are being studied in 12 ongoing Phase 2 clinical trials, focused on cancer and rare diseases. The Company�� two advanced protein therapeutic candidates, sotatercept and ACE-536, promote red blood cell production through a novel mechanism. Together with its collaboration partner, Celgene Corporation, the Company is developing sotatercept and ACE-536 to treat anemia and associated complications in patients with b-thalassemia and myelodysplastic syndromes (MDS). These red blood cell disorders are generally unresponsive to approved dru! gs. The Company�� third clinical stage protein therapeutic candidate, dalantercept, is designed to inhibit blood vessel formation through a mechanism that is distinct from, and potentially synergistic with, the dominant class of cancer drugs that inhibit blood vessel formation, the vascular endothelial growth factor (VEGF) pathway inhibitors. The Company is developing dalantercept primarily for use in combination with these products to produce better outcomes for cancer patients.
The Company and Celgene have conducted six human clinical trials with sotatercept in over 160 healthy volunteers and cancer patients. The Company has conducted one clinical trial with ACE-536 in healthy volunteers. In these studies, both sotatercept and ACE-536 caused a dose-dependent increase in the number of red blood cells. Based on these results, the Company and Celgene have initiated Phase II clinical trials with each of these protein therapeutic candidates in b-thalassemia and MDS. In the ongoing trial of sotatercept in patients with b-thalassemia, the Company has observed encouraging, dose-dependent increases in hemoglobin in a subset of patients at the two lowest dose levels.
Sotatercept is a soluble receptor fusion protein consisting of the extracellular domain of the activin receptor type IIA (ActRIIA) linked to the Fc domain of human IgG1. Sotatercept acts as a protein trap for TGF-b superfamily ligands that signal through the ActRIIA receptor. Sotatercept has increased red blood cells in multiple clinical trials. ACE-536 is a soluble receptor fusion protein consisting of a modified extracellular domain of the activin receptor type IIB (ActRIIB) linked to the Fc domain of human IgG1.
Advisors' Opinion:- [By John Udovich]
Yesterday, small cap biotech Acceleron Pharma Inc (NASDAQ: XLRN) rose 9.76%�plus shares are up 183.6% for retail investors since its September IPO, meaning its worth taking a closer look at the stock along with the performance of other biotech IPOs like BIND Therapeutics Inc (NASDAQ: BIND), Ophthotech Corp (NASDAQ: OPHT) and Foundation Medicine Inc (NASDAQ: FMI) which also debuted at the same time.
- [By Jake L'Ecuyer]
Shares of Acceleron Pharma (NASDAQ: XLRN) got a boost, shooting up 16.74 percent to $39.54 after Form 8-K for Acceleron Pharma showed that Celgene (NASDAQ: CELG) will buy 1.1 million shares for $47.15 million.
- [By Ben Levisohn]
3. We see 23+ partnered pipeline assets and are most positive on Phase I/II MOR202 anti-CD38 for myeloma with data in 2015, and others such as Acceleron Pharma (XLRN), Agios Pharmaceuticals (AGIO), Epizyme (EPZM), Concert Pharmaceuticals (CNCE) (just started Phase I for next-gen Revlimid).
- [By Jake L'Ecuyer]
Shares of Acceleron Pharma (NASDAQ: XLRN) got a boost, shooting up 16.39 percent to $39.42 after Form 8-K for Acceleron Pharma showed that Celgene (NASDAQ: CELG) will buy 1.1 million shares for $47.15 million.
Top Rising Stocks To Watch Right Now: China Mobile(Hong Kong)
China Mobile Limited, an investment holding company, provides mobile telecommunications and related services primarily in the Mainland China. It offers various services comprising local calls, domestic long distance calls, international long distance calls, domestic roaming, and international roaming. The company also provides voice value-added services, including caller identity display, caller restrictions, call waiting, call forwarding, call holding, voice mail, and conference calls; customer-to-customer messages and corporate short message services; and mobile Internet access services. In addition, it engages in other data businesses, which primarily include multimedia messaging services; color ring services that enable users to customize the answer ring tone from various selection of songs, melodies, sound effects, or voice recordings; and mobile reading, mobile gaming, mobile video, mobile payment/wallet, mobile TV, mobile market, and Internet data center services. F urther, the company offers telecommunications network planning, design, and consulting services; roaming clearance services; technology platform development and maintenance services; and mobile data solutions, and system integration and development services, as well as operates a network and business coordination center. Additionally, China Mobile Limited sells mobile phone handsets and devices. As of March 31, 2011, it served approximately 600.8 million customers. The company was formerly known as China Mobile (Hong Kong) Limited and changed its name to China Mobile Limited in May 2006. China Mobile was founded in 1997. The company is based in Central, Hong Kong, and is considered a Red Chip company due to its listing on the Hong Kong Stock Exchange. China Mobile Limited is a subsidiary of China Mobile Hong Kong (BVI) Limited.
Advisors' Opinion:- [By GuruFocus]
China Mobile Ltd. was incorporated under the laws of Hong Kong on Sept. 3, 1997, as a limited liability company under the name China Telecom (Hong Kong) Limited. China Mobile Ltd. has a market cap of $194.9 billion; its shares were traded at around $48.48 with a P/E ratio of 9.70 and P/S ratio of 2.20. The dividend yield of China Mobile Ltd. stocks is 4.20%. China Mobile Ltd. had an annual average earnings growth of 16.60% over the past 10 years. GuruFocus rated China Mobile Ltd.�the business predictability rank of 3.5-star.
Top Rising Stocks To Watch Right Now: Ituran Location and Control Ltd (ITRN)
Ituran Location and Control Ltd. (Ituran), incorporated in February 1994, is engaged in the provision of location-based services and machine-to-machine wireless communications products for use in stolen vehicle recovery, fleet management and other applications. The Company operates in two segments: location-based services and wireless communication products. During the year ended December 31, 2012, 76.2% of its revenues were attributable to its location-based services. As of December 31, 2012, Ituran provided its services in Israel, Brazil, Argentina and the United States to approximately 276,000, 238,000, 131,000 and 22,000 subscribers, respectively. In 2012, 23.8% of its revenues were attributable to the sale of its wireless communications products.
Location-Based Services
The Company�� stolen vehicle recovery and tracking services, which it refer to as SVR services, enable it to locate, track and recover stolen vehicles for its subscribers. The Company�� customers include both individual vehicle owners who subscribe to its services directly and insurance companies that either require their customers to install a security system or offer their customers financial incentives to subscribe to SVR services, such as its. In certain countries, insurance companies directly subscribe to its SVR services and purchase automatic vehicle location (AVL) products supporting these SVR services from us on behalf of their customers. The Company�� fleet management services enable corporate customers to track and manage their vehicle. It markets and sells its services to a range of vehicle fleet operators in different geographic locations and industries. As of December 31, 2012, the Company provided its services to approximately 81,000 end-users through 21,000 corporate customers in Israel, Brazil, Argentina and the United States.
Personal locator services, which it offers allow customers to protect merchandise and equipment. In addition, through a call center it provides ! 24-hour round the clock on-demand navigation guidance, information and assistance to its customers. As of December 31, 2012, the Company provided personal locator services in Israel, Brazil and Argentina and, as of December 31, 2012, it had approximately 7,500 subscribers to this service. The Company�� call center services include the provision of traffic reports, help with directions and information on the location gas stations, car repair shops, post offices, hospitals and other facilities. The Company provides its concierge services to its subscribers in Israel, Argentina and Brazil. As of December 31, 2012, it had approximately 128,000 subscribers to its concierge service
Wireless Communications Products
The Company�� wireless communications products employ short- and medium-range communication between two-way wireless modems and are used for various applications, including AVL. Its AVL products enable the location and tracking of vehicles, as well as assets and persons, and are used by it primarily to provide SVR and fleet management services to its customers. Each subscriber to its SVR services has its AVL end-unit installed in his or her vehicle. Subscribers to services for locating equipment and merchandise will use its SMART products. The Company�� wireless communications products for AVL applications include: Base Site, Control Center, global positioning systems/ beneral packet radio service (GPS/GPRS)-based products and SMART. Base Site is a radio receiver, which includes a processor and a data computation unit to collect and send data to and from transponders and send that data to control centers as part of the terrestrial infrastructure of the location system. Control Center is a center, which consists of software used to collect data from various base sites, conduct location calculations and transmit location data to various customers and law enforcement agencies.
Global positioning systems/ beneral packet radio service (GPS/GPRS)-based products! include ! navigation and tracking devices installed in vehicles. SMART is a portable transmitter installed in vehicles (including motorcycles) that sends a signal to the base site, enabling the location of vehicles, equipment or an individual. The Company maintains 103 base stations in Israel. The provides radio frequency (RF) based products and services only in the metropolitan areas of Sao Paulo, Campinas, Americans and Rio de Janeiro, in Brazil. It operates throughout Brazil in providing GPS/GPRS based products and services. The Company operates only in the metropolitan area of Buenos Aires with the RF technology, in Argentina. The Company operates throughout Argentina in providing GPS/GPRS based products and services for fleet management. It provides GPS/GPRS products and services throughout the United States.
The Company competes with Eden Telecom Ltd. (Pointer), Skylock Ltd, LoJack Corporation, Car System, Megatrans, Pointer Localizacion y Asistencia S.A, OnStar Corporation, Sky Link Corporation, Spireon, Air Cept Corporation, SysLocate, GoldStar, PassTime, Guide Point, Sky Patrol, Sky Guard, I-Metrik, GPS Insight, Trimble, Network Fleet, Street Eagle, FleetMatics , Navtrack, Teletrac, Trim Track, FleetBoss, Sascar, Omnilink and Hawk Corporation.
Advisors' Opinion:- [By Matthew Indyke and Brian Zen]
Four of Klarman�� stocks include PDLBioPharma (PDLI), Ituran Location and Control (ITRN), BP (BP), and Microsoft (MSFT). What these companies have in common are annually increasing total revenues, annually increasing cash flows, and gradually decreasing operating expenses and debt. Additionally, they show a clear value focus with P/E ratios no greater than 15. And even when stocks like these go through a troubling period brought on by a sagging economy or major scandal, they have an ability to bounce back.
Top Rising Stocks To Watch Right Now: Anadolu Efes Biracilik ve Malt Sanayii AS (AEFES)
Anadolu Efes Biracilik ve Malt Sanayii AS is the holding company of Efes Beverage Group, based in Turkey. Its activities consist of production, bottling, selling and distribution of beer under a number of trademarks and also production, bottling, selling and distribution of sparkling and still beverages with the Coca-Cola company trademark. The Company owns and operates a number of breweries in Turkey and abroad, malt production facilities in Turkey and Russia, and also a number of facilities in Turkey and in other countries for sparkling and still beverages production. It has joint control over Coca-Cola Icecek AS (CCI), which undertakes production, bottling and distribution facilities of Coca-Cola products in Turkey, Pakistan, Central Asia and the Middle East. Also the Company has joint control over Anadolu Etap Tarm ve Gda Urunleri San. ve Tic. AS, which undertakes production and sales of fruit juice concentrates and purees in Turkey. Advisors' Opinion:- [By Andras Gergely]
The Borsa Istanbul Stock Exchange National 100 Index slid a second day after reaching a record on May 22. Anadolu Efes (AEFES) sank the most since September 2011. Otokar Otomotiv ve Savunma Sanayi AS, a Turkish producer of civilian and military vehicles, rose to an all-time high after Hurriyet Daily News reported the company could sell tanks to Saudi Arabia.
Top Rising Stocks To Watch Right Now: CDW Corp (CDW)
CDW Corporation (CDW), incorporated on May 25, 2007, is a provider of integrated information technology (IT) solutions in the United States and Canada. Its range of offerings range from discrete hardware and software products to integrated IT solutions, such as mobility, security, data center optimization, cloud computing, virtualization and collaboration. The Company has two segments: Corporate and Public. Corporate segment consists of primarily of private sector business customers. Public segment consists of government agencies and education and healthcare institutions. CDW also has two other operating segments, CDW Advanced Services and Canada (combined together as Other). The Company is a sales channel partner for many original equipment manufacturers (OEMs) and software publishers (collectively, its vendor partners), whose products it sells or include in the solutions CDW offers. The Company helps its customer base of more than 250,000 small, medium and large business, government, education and healthcare customers by delivering solutions to their IT needs.
The Company�� Corporate segment is divided into a medium-large business customer channel, primarily serving customers with more than 100 employees, and a small business customer channel, primarily serving customers with up to 100 employees. The CDW Advanced Services business consists primarily of customized engineering services delivered by technology specialists and engineers and managed services that include infrastructure as a service (IaaS) offerings. The Company�� product portfolio includes more than 100,000 products from more than 1,000 brands. Revenues from the sale of hardware, software, custom configuration and third-party provided services are recorded within its Corporate and Public segments.
The Company�� revenue from professional services is either recognized as incurred for services billed at an hourly rate or recognized using a proportional performance model for services provided at a fixed fee.! Revenue from software as a service (SaaS) arrangements, IaaS arrangements, and data center services, including Internet connectivity, Web hosting, server co-location and managed services, is recognized over the period service is provided. The Company also sells certain products for which it acts as an agent. Products in this category include the sale of third-party services, warranties or software assurance (SA) or third-party-hosted SaaS and IaaS arrangements. The Company offer over 1,000 brands, from companies, such as APC, Apple, Cisco, EMC, Hewlett-Packard, IBM, Lenovo, Microsoft, NetApp, Symantec and VMware, to vendor partners, such as Drobo, Fusion-io, Meraki, Nimble Storage, Salesforce.com, Sophos and Splunk.
The Company competes with Dimension Data, ePlus, Insight Enterprises, PC Connection, PCM, Presidio, Softchoice, World Wide Technology, Dell, Hewlett-Packard, Apple, Amazon, Newegg, TigerDirect.com, Buy.com, IBM, Accenture, Staples, Office Depot and Office Max.
Advisors' Opinion:- [By Rich Smith]
Just over six years after leaving the public stock markets in a $7.3 billion leveraged buyout, IT equipment supplier CDW (NASDAQ: CDW ) is back on the Nasdaq again!
- [By Jon C. Ogg]
Before you consider this just to be a bit of IPO pondering, take a step back and understand that some of this list membership already has�filed to come public or actually has�made it public recently. Boise Cascade Co. (NYSE: BCC), CDW Corp. (NASDAQ: CDW), Coty Inc. (NYSE: COTY), Global Brass and Copper Holdings Inc. (NYSE: BRSS), Noodles & Company (NASDAQ: NDLS), Restoration Hardware Holdings Inc. (NYSE: RH), Sprouts Farmers Market Inc. (NASDAQ: SFM) and many others are on the list and have made it to the post-IPO stage in the stock market.
Top Rising Stocks To Watch Right Now: Acorda Therapeutics Inc.(ACOR)
Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its marketed products include Ampyra (dalfampridine), a potassium channel blocker for improving walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS with walking disability under the Fampyra name internationally. Its lead research and development programs include three biologic therapeutic approaches for restoring neurologic and cardiac function, which comprise Neuregulin Program for developing Glial Growth Factor 2, a molecule in the Phase I clinical trial for the treatment of heart failure; Remyelina ting Antibodies Program for developing rHIgM22, an antibody in the preclinical stage for treating MS; and Chondroitinase Program, a research stage program focused on developing chontroitinase as a therapeutic to break down inhibitory factors in the scar tissue that develops as a result of an injury to the CNS. In addition, the company has in-licensed a clinical-stage program, AC105, to develop an acute treatment for neurological trauma. It has collaboration agreement with Biogen Idec International GmbH to develop and commercialize products containing aminopyridines to the treatment of MS. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Hawthorne, New York.
Advisors' Opinion:- [By James E. Brumley]
Investors who were hoping things would work out for epilepsy treatment company Cyberonics, Inc. (NASDAQ:CYBX) can cross CYBX off their list of epilepsy-oriented stocks to buy, as they did with Acorda Therapeutics Inc. (NASDAQ:ACOR) about a month ago. ACOR saw its epilepsy drug Plumiaz rejected by the FDA in early May, while CYBX announced this morning that the coming fiscal year's (beginning in April) revenue would be weaker than first expected as sales of its epileptic control implant device didn't look quite as promising as hoped.